Get the Stockscreener App
3.75
3.59%
0.13
After Hours:
3.75
Zura Bio Ltd stock is traded at $3.75, with a volume of 1.76M.
It is up +3.59% in the last 24 hours and down -8.98% over the past month.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
See More
Previous Close:
$3.62
Open:
$3.63
24h Volume:
1.76M
Relative Volume:
2.37
Market Cap:
$355.80M
Revenue:
-
Net Income/Loss:
$-75.43M
P/E Ratio:
-3.0735
EPS:
-1.2201
Net Cash Flow:
$-72.75M
1W Performance:
+4.75%
1M Performance:
-8.98%
6M Performance:
-12.18%
1Y Performance:
+237.84%
1-Day Range:
$3.52
$3.795
1-Week Range:
$3.51
$3.855
52-Week Range:
$1.00
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
3.75 | 355.80M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Stockanalyst focus on early-stage pipeline - AD HOC NEWS
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Jessica Chen - White & Case LLP
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura says it has enough cash to operate through 2028 as two trials advance - Stock Titan
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio | DEF 14A: Definitive information statements - Moomoo
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio | ARS: Annual Report to Security Holders - Moomoo
[ARS] Zura Bio Ltd SEC Filing - Stock Titan
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio Limited 8-K Filing Details April 2026 – Separation Agreement, Company Information, and SEC Compliance - Minichart
Zura Bio LtdEric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
Zura Bio : Corporate Overview April 2026 (d9fec3) - marketscreener.com
Zura Bio Limited Announces CFO Changes, Effective April 20, 2026 - marketscreener.com
[8-K] Zura Bio Ltd Reports Material Event - Stock Titan
One Zura Bio Insider Raised Their Stake In The Previous Year - Yahoo Finance
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering - Benzinga
JATT Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
JATT Technical Analysis & Stock Price Forecast - Intellectia AI
JATT PE Ratio & Valuation, Is JATT Overvalued - Intellectia AI
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):